Effect of A.C.T.H. On Hair Growth in Alopecia Areata and Universalis

Wilson, R.Douglas

doi:10.1016/s0140-6736(52)90162-1

Cited by 11 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wilson successfully treats AA patients with adrenocorticotropic hormone (ACTH). [218] 1952 Dillaha and Rothman first use oral systemic cortisone acetate to successfully treat AA. The mechanism of efficacy is unknown.…”

mentioning

confidence: 99%

A “hair‐raising” history of alopecia areata

Broadley

McElwee

2020

Experimental Dermatology

View full text Add to dashboard Cite

A 3500‐year‐old papyrus from ancient Egypt provides a list of treatments for many diseases including “bite hair loss,” most likely alopecia areata (AA). The treatment of AA remained largely unchanged for over 1500 years. In 30 CE, Celsus described AA presenting as scalp alopecia in spots or the “windings of a snake” and suggested treatment with caustic compounds and scarification. The first “modern” description of AA came in 1813, though treatment still largely employed caustic agents. From the mid‐19th century onwards, various hypotheses of AA development were put forward including infectious microbes (1843), nerve defects (1858), physical trauma and psychological stress (1881), focal inflammation (1891), diseased teeth (1902), toxins (1912) and endocrine disorders (1913). The 1950s brought new treatment developments with the first use of corticosteroid compounds (1952), and the first suggestion that AA was an autoimmune disease (1958). Research progressively shifted towards identifying hair follicle‐specific autoantibodies (1995). The potential role of lymphocytes in AA was made implicit with immunohistological studies (1980s). However, studies confirming their functional role were not published until the development of rodent models (1990s). Genetic studies, particularly genome‐wide association studies, have now come to the forefront and open up a new era of AA investigation (2000s). Today, AA research is actively focused on genetics, the microbiome, dietary modulators, the role of atopy, immune cell types in AA pathogenesis, primary antigenic targets, mechanisms by which immune cells influence hair growth, and of course the development of new treatments based on these discoveries.

show abstract

mentioning

confidence: 99%

A “hair‐raising” history of alopecia areata

Broadley

McElwee

2020

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…Adrenocorticotrophic hormone (ACTH) by injection and corti costeroids by m outh were first advocated for alopecia areata, alopecia totalis and alopecia universalis in 1952 [1][2][3]. Although superior to other agents previously used for these disorders, the systemic adm inistration of corticosteroids was found to be generally inadvisab le because of the large doses required to stim ulate and m aintain regrowth of hair [4,5].…”

Section: Introductionmentioning

confidence: 99%

Assay of 0.2 % Fluocinolone Acetonide Cream for Alopecia Areata and Totalis

Pascher¹,

Kurtin²,

Andrade³

1970

Dermatology

View full text Add to dashboard Cite

A paired comparison of the efficacy of a topically applied fluoridated corticosteroid, 0.2% fluocinolone acetonide in a cream base (Synalar-HP®, Syntex) and the base alone was carried out in 28 patients with alopecia areata and alopecia totalis. A satisfactory to excellent therapeutic response was obtained in 17/28 patients (61%), with the corticosteroid cream treatment. The patient’s age and the duration of the alopecia appeared to be important factors in the outcome. Although relapses were encountered in 11/17 patients (63%) during the course of treatment or within 3 months after treatment was discontinued, 12/17 (71%) of those who responded did retain sufficient regrowth for the result to be considered satisfactory. The only troublesome complication was the development of a localized acneform eruption in 5/28 patients (18%) between the ages of 15 and 25 years. None of the patients developed clinical evidence of systemic absorption.

show abstract

“…Urinalysis revealed intermittent pyuria, and intravenous pyelogram suggested chronic pyelonephritis. A 24-hour urinary 17-ketosteroid determination was 8.6 mg/24 hr (normal 9-22 mg/24 hr in males) ; 24-hour 17ketogenic steroid determination was 7.3 mg/24 hr (normal, [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] mg/24 hr in males). On June 12, 1962, skin biopsy was performed with specimens obtained from the beard area, the scalp, and the dorsal surface of the forearm.…”

mentioning

confidence: 99%

Steroid Therapy in Alopecia Universalis

Darvill¹

1963

Arch Dermatol

View full text Add to dashboard Cite

Effect of A.C.T.H. On Hair Growth in Alopecia Areata and Universalis

Cited by 11 publications

References 6 publications

A “hair‐raising” history of alopecia areata

A “hair‐raising” history of alopecia areata

Assay of 0.2 % Fluocinolone Acetonide Cream for Alopecia Areata and Totalis

Steroid Therapy in Alopecia Universalis

Contact Info

Product

Resources

About